Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability